Guardant Health (GH) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
The meeting was called to order shortly after 9:30 A.M. Pacific time and conducted virtually to maximize accessibility for stockholders.
Stockholders were informed about the procedures for voting and asking questions, with rules of conduct and agenda available on the web portal.
Only stockholders of record as of April 15, 2024, were eligible to participate in voting and Q&A.
Board and executive committee updates
The meeting was chaired by the Co-CEO, with participation from the Board of Directors and representatives from the independent auditor and legal counsel.
Three individuals were nominated for election as Class 3 directors for a three-year term.
Shareholder proposals
Three proposals were presented: election of Class 3 directors, ratification of the independent auditor, and advisory approval of executive compensation.
Latest events from Guardant Health
- AI-driven liquid biopsy innovation and robust 2025 growth set up major launches for 2026.GH
44th Annual J.P. Morgan Healthcare Conference15 Apr 2026 - 2025 revenue up 33% to $982M; 2026 outlook targets 27–30% growth and Shield expansion.GH
Q4 202511 Apr 2026 - First-of-its-kind monitoring CDx and rapid Shield adoption fuel strong growth outlook.GH
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Quest partnership and new guidelines drive Shield and Guardant360 growth, boosting revenue outlook.GH
Leerink Global Healthcare Conference 202610 Mar 2026 - Strong growth and innovation across all product lines, with major regulatory and commercial catalysts ahead.GH
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - FDA approved Shield as the first blood-based, first-line CRC screening for average-risk adults.GH
FDA Announcement2 Feb 2026 - Q2 revenue up 29% to $177.2M; Shield test FDA approved; 2024 guidance raised to $700M.GH
Q2 20242 Feb 2026 - Innovators are advancing cancer screening with diverse technologies and a focus on evidence and access.GH
UBS Genomic Medicine Summit2 Feb 2026 - Shield's FDA approval and rapid growth set the stage for major expansion and profitability in 2025.GH
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026